Literature DB >> 26103125

Circulating tissue inhibitor of matrix metalloproteinase-1 is associated with aldosterone-induced diastolic dysfunction.

Chi-Sheng Hung1, Chia-Hung Chou, Xue-Ming Wu, Yi-Yao Chang, Vin-Cent Wu, Ying-Hsien Chen, Yuan-Shian Chang, Yao-Chou Tsai, Ming-Jai Su, Yi-Lwun Ho, Ming-Fong Chen, Kwan-Dun Wu, Yen-Hung Lin.   

Abstract

OBJECTIVE: To test if collagen markers are associated with aldosterone-induced diastolic dysfunction.
BACKGROUND: Although primary aldosteronism is associated with more prominent cardiac remodeling and diastolic dysfunction, the reversibility of diastolic function is unclear. In addition, there is no known biomarker associated with aldosterone-induced diastolic dysfunction.
METHODS: We enrolled 27 patients with aldosterone-producing adenoma (APA) preparing for adrenalectomy, and 27 patients with essential hypertension prospectively from October 2006 to March 2010 at a tertiary referral center. Plasma matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) were measured, and echocardiography including tissue Doppler images was performed in both groups and 1 year after receiving adrenalectomy in the APA group.
RESULTS: The baseline plasma TIMP-1 level (88.4 ± 38.7 vs. 63.6 ± 32.5 ng/ml; P = 0.014), left ventricular mass index (LVMI), and E/E' ratio (11.5 ± 2.9 vs. 9.0 ± 2.1; P < 0.001) were significantly higher in the APA group. The baseline plasma TIMP-1 level significantly correlated with the E/E' ratio, LVMI, interventricular septum, and left atrial diameter. The plasma MMP-2 level did not correlate with the left ventricular structure parameters, except for interventricular septum thickness. After adrenalectomy, LVMI and E/E' ratio improved significantly. The postadrenalectomy plasma TIMP-1 levels, but not MMP-2 levels, also decreased. The change of plasma TIMP-1 levels was negatively associated with the postadrenalectomy E/E' ratio after adjustment for age, sex, BMI, and mean blood pressure (β-coefficient = - 3.6, P = 0.004).
CONCLUSION: Excess of aldosterone induces cardiac diastolic dysfunction, which is reversible by adrenalectomy. TIMP-1 is associated with the aldosterone-induced diastolic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26103125     DOI: 10.1097/HJH.0000000000000619

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  9 in total

1.  Treatment of Primary Aldosteronism and Reversal of Renin Suppression Improves Left Ventricular Systolic Function.

Authors:  Troy H Puar; Chin Kai Cheong; Roger S Y Foo; Seyed Ehsan Saffari; Tian Ming Tu; Min Ru Chee; Meifen Zhang; Keng Sin Ng; Kang Min Wong; Andrew Wong; Foo Cheong Ng; Tar Choon Aw; Joan Khoo; Linsey Gani; Thomas King; Wann Jia Loh; Shui Boon Soh; Vanessa Au; Tunn Lin Tay; Eberta Tan; Lily Mae; Jielin Yew; Yen Kheng Tan; Khim Leng Tong; Sheldon Lee; Siang Chew Chai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-30       Impact factor: 6.055

Review 2.  Left ventricular remodeling and dysfunction in primary aldosteronism.

Authors:  Cheng-Hsuan Tsai; Chien-Ting Pan; Yi-Yao Chang; Zheng-Wei Chen; Vin-Cent Wu; Chi-Sheng Hung; Yen-Hung Lin
Journal:  J Hum Hypertens       Date:  2020-10-16       Impact factor: 3.012

3.  The relationship between serum fibrosis markers and restrictive ventricular filling in patients with heart failure with reduced ejection fraction: A technetium-99m radionuclide ventriculography study.

Authors:  Yen-Tin Lin; Yen-Hung Lin; Xue-Ming Wu; Chi-Lun Ko; Ruoh-Fang Yen; Ying-Hsein Chen; Ron-Bin Hsu; Chi-Ming Lee; Shoei-Shen Wang; Ming-Fong Chen; Yen-Wen Wu
Journal:  Oncotarget       Date:  2017-01-10

4.  Influence of Different Treatment Strategies on New-Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort-Based Study.

Authors:  Chien-Ting Pan; Che-Wei Liao; Cheng-Hsuan Tsai; Zheng-Wei Chen; Likwang Chen; Chi-Sheng Hung; Yu-Chen Liu; Po-Chih Lin; Chin-Chen Chang; Yi-Yao Chang; Vin-Cent Wu; Yen-Hung Lin
Journal:  J Am Heart Assoc       Date:  2020-02-19       Impact factor: 5.501

5.  Serum Matrix Metalloproteinases and Left Atrial Remodeling-The Hoorn Study.

Authors:  Pauline B C Linssen; Hans-Peter Brunner-La Rocca; Casper G Schalkwijk; Joline W J Beulens; Petra J M Elders; Amber A van der Heijden; Roderick C Slieker; Coen D A Stehouwer; Ronald M A Henry
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

6.  The paradoxical effect of aldosterone on cardiovascular outcome in maintenance hemodialysis patients.

Authors:  Sun Ryoung Choi; Young-Ki Lee; Hayne Cho Park; Do Hyoung Kim; AJin Cho; Juhee Kim; Kyu Sang Yun; Jung-Woo Noh; Min-Kyung Kang
Journal:  Kidney Res Clin Pract       Date:  2021-11-30

7.  New-Onset Atrial Fibrillation in Patients With Primary Aldosteronism Receiving Different Treatment Strategies: Systematic Review and Pooled Analysis of Three Studies.

Authors:  Cheng-Hsuan Tsai; Ya-Li Chen; Chien-Ting Pan; Yen-Tin Lin; Po-Chin Lee; Yu-Wei Chiu; Che-Wei Liao; Zheng-Wei Chen; Chin-Chen Chang; Yi-Yao Chang; Chi-Sheng Hung; Yen-Hung Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-24       Impact factor: 5.555

8.  Rationale and Design for a Monocentric Prospective Study: Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction (SAPAAD Study).

Authors:  Laure Champ-Rigot; Virginie Ferchaud; Jean-Noël Prévost; Pierre Moirot; Arnaud Pellissier; Damien Legallois; Joachim Alexandre; Patrice Scanu; Remy Morello; Eric Saloux; Paul Ursmar Milliez
Journal:  Clin Med Insights Cardiol       Date:  2018-01-08

9.  Left Ventricular Dysfunction in Patients With Primary Aldosteronism: A Propensity Score-Matching Follow-Up Study With Tissue Doppler Imaging.

Authors:  Yi-Yao Chang; Che-Wei Liao; Cheng-Hsuan Tsai; Ching-Way Chen; Chien-Ting Pan; Zheng-Wei Chen; Ya-Li Chen; Lung-Chun Lin; Yi-Ru Chang; Vin-Cent Wu; Kwan-Dun Wu; Chi-Sheng Hung; Yen-Hung Lin
Journal:  J Am Heart Assoc       Date:  2019-11-13       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.